CLINICAL TRIALS AND OBSERVATIONS Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study
نویسندگان
چکیده
1Van Creveldkliniek, University Medical Center Utrecht, the Netherlands; 2Department of Pediatrics, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, the Netherlands; 3Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands; 4Prof Hess-Kinderklinik, Zentrum fur Kinderheilkunde und Jugendmedizin, Bremen, Germany; 5Centre of Pediatrics III, Department of Hematology, Oncology and Haemostaseology, Johann-Wolfgang-Goethe University Hospital, Frankfurt AM Main, Germany; 6Department of Pediatrics, University of Lund, University Hospital, Malmö, Sweden
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study
The CANAL Study (Concerted Action on Neutralizing Antibodies in severe hemophilia A) was designed to describe the relationship between treatment characteristics and inhibitor development in previously untreated patients with severe hemophilia A. This multicenter retrospective cohort study investigated 366 consecutive patients born between 1990 and 2000. The outcome was clinically relevant inhib...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients
Current factor VIII (FVIII) products display a half-life (t1/2) of 8-12 hours, requiring frequent intravenous injections for prophylaxis and treatment of patients with hemophilia A. rFVIIIFc is a recombinant fusion protein composed of a single molecule of FVIII covalently linked to the Fc domain of human IgG1 to extend circulating rFVIII t1/2. This first-in-human study in previously treated sub...
متن کاملRegular Article CLINICAL TRIALS AND OBSERVATIONS Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011
Department of Haematology, University Hospital of Wales, School of Medicine, Cardiff, United Kingdom; The UK National Haemophilia Database, Manchester, United Kingdom; Department of Haematology, Royal Hospital for Sick Children, Glasgow, United Kingdom; The Haemophilia Centre, The Royal London Hospital, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, Unit...
متن کاملPlenary Paper CLINICAL TRIALS AND OBSERVATIONS Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A
Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A Johnny Mahlangu, Jerry S. Powell, Margaret V. Ragni, Pratima Chowdary, Neil C. Josephson, Ingrid Pabinger, Hideji Hanabusa, Naresh Gupta, Roshni Kulkarni, Patrick Fogarty, David Perry, Amy Shapiro, K. John Pasi, Shashikant Apte, Ivan Nestorov, Haiyan Jiang, Shuanglian Li, Srividya Neelakantan, Lynda M. Cristiano, ...
متن کاملCLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates
Human plasma–derived factor IX (pdFIX) concentrates are routinely used to treat patients with hemophilia B, an X-linked bleeding disorder that affects 1 in 30 000 males, but concerns remain regarding transmission of blood-borne pathogens. Therefore, the safety and efficacy of recombinant human factor IX (rFIX) were evaluated. A 20-center international trial was conducted in previously treated p...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2007